Welcome to our dedicated page for Legend Biotech news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech stock.
Legend Biotech Corporation (NASDAQ: LEGN) generates frequent news as a global cell therapy company focused on CAR‑T treatments for cancer. News coverage for Legend Biotech often centers on CARVYKTI® (ciltacabtagene autoleucel; cilta‑cel), its BCMA‑targeted CAR‑T cell therapy for relapsed or refractory multiple myeloma, as well as updates on its broader pipeline of cell therapy programs.
Investors and observers following LEGN news can expect regular announcements on clinical data from the CARTITUDE program in multiple myeloma, including long‑term progression‑free survival results and analyses of earlier‑line use. Company press releases also highlight presentations at major medical meetings such as the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the European Hematology Association (EHA), where Legend Biotech shares outcomes from CARVYKTI and investigational candidates like LUCAR‑G39D, LB2102, and LB1908.
Legend Biotech’s news flow includes regulatory milestones, such as FDA and European Commission label updates for CARVYKTI to incorporate overall survival data and new safety information. The company also reports on manufacturing and infrastructure developments, including expansion of its Raritan, New Jersey cell therapy facility and commercial production in Ghent, Belgium, which are intended to support growing global demand.
Quarterly earnings releases and related Form 6‑K filings provide financial updates on collaboration revenue from CARVYKTI, license revenue from agreements with partners, operating expenses, cash and time deposits, and progress toward profitability. Corporate news items may also cover executive appointments, participation in investor conferences, and strategic priorities outlined at healthcare investment events.
For users tracking LEGN, this news page offers a centralized view of Legend Biotech’s clinical, regulatory, manufacturing, and financial announcements, helping contextualize the company’s evolution in the cell therapy and oncology landscape.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Exelixis, Inc. (Nasdaq: EXEL) announced that Carl Feldbaum and Vincent Marchesi will not seek re-election to the Board of Directors during the 2023 Annual Meeting of Stockholders. The Board is nominating Tomas Heyman and Robert Oliver as independent directors to fill their positions. This decision follows unsuccessful settlement negotiations with Farallon Capital Management regarding board member nominations and access to company information. Dr. Stelios Papadopoulos expressed gratitude toward Feldbaum and Marchesi for their service. The upcoming board election aims to enhance corporate governance. Following the election, the Board will consist of 11 members, 10 of whom are independent. The Annual Meeting date has yet to be announced.
Legend Biotech Corporation (NASDAQ: LEGN) has appointed Mythili Koneru, M.D., Ph.D. as its new Chief Medical Officer. Dr. Koneru previously served at Marker Therapeutics where she led the development of cell therapies and peptide vaccines. Her extensive background includes roles at Eli Lilly, focusing on immuno-oncology clinical development, and an oncology fellowship at Memorial Sloan-Kettering Cancer Center. CEO Ying Huang expressed confidence in Dr. Koneru's expertise in immunotherapy and cell therapy, emphasizing her role in advancing the company's pipeline. Dr. Koneru holds a B.A. in Cellular and Molecular Biology from the University of Chicago, a Ph.D. in Tumor Immunology from New York University, and an M.D. from Robert Wood Johnson Medical School.
The report titled "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023" has been released by ResearchAndMarkets.com. This comprehensive report offers insights into partnering deals in the pharmaceutical and biotechnology sectors, including details on technology licensed, royalty rates, license fees, and other payments. It covers all disclosed deals since 2010, providing essential data for prospective dealmakers. Key chapters analyze royalty rate trends, the structure of royalty clauses, and leading companies in the field. The report aims to equip readers with the necessary tools for effective negotiations and due diligence in licensing agreements.
The CAR-T Therapy Pipeline Analysis Global Market Report 2023 has been released by ResearchAndMarkets.com, detailing significant growth in the CAR-T therapy market. The market is projected to expand from $1.40 billion in 2021 to $1.80 billion in 2022, reflecting a CAGR of 28.6%. By 2026, the market is expected to reach $3.55 billion, growing at a CAGR of 18.5%. Major players include Legend Biotech, Novartis AG, and Kite Pharma. The report highlights the role of financial support for CAR-T therapy development and notes the impact of high costs and limitations in treating certain cancers as challenges. The leading regions are North America and Western Europe, while the main product types include monotherapy and combination therapy targeting cancers such as acute lymphoblastic leukemia.
Legend Biotech Corporation (NASDAQ: LEGN) has formed a new strategic advisory board, appointing Michel Vounatsos, former CEO of Biogen, and John Maraganore, PhD, former CEO of Alnylam Pharmaceuticals, as advisors. Both will collaborate with the company's leadership to enhance its cell therapy platforms and propel growth objectives. Vounatsos brings significant experience from Biogen and Merck, while Maraganore is recognized for his pivotal role in developing RNA interference therapeutics. The appointments aim to leverage their extensive industry backgrounds for advancing Legend Biotech's mission in treating life-threatening diseases.